Last reviewed · How we verify
Cervoxan (eburnamonine)
Cervoxan (generic name: eburnamonine) is a drug. It is currently in unknown development.
Cervoxan works by binding to the muscarinic acetylcholine receptor M3, which is involved in various physiological processes.
Vinburnine, also known as Cervoxan, is a small molecule vasodilator. It is a vinca alkaloid and a metabolite of vincamine.
At a glance
| Generic name | eburnamonine |
|---|---|
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's 'communication system' uses chemical messengers to send signals between cells. Cervoxan helps block one type of signal, called acetylcholine, from binding to its receptor on certain cells. This can affect how these cells function, which may help treat certain conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cervoxan CI brief — competitive landscape report
- Cervoxan updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Cervoxan
What is Cervoxan?
How does Cervoxan work?
What is the generic name of Cervoxan?
What development phase is Cervoxan in?
What does Cervoxan target?
Related
- Target: All drugs targeting Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing